These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH; J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588 [TBL] [Abstract][Full Text] [Related]
11. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. Loré K; Adams WC; Havenga MJ; Precopio ML; Holterman L; Goudsmit J; Koup RA J Immunol; 2007 Aug; 179(3):1721-9. PubMed ID: 17641038 [TBL] [Abstract][Full Text] [Related]
12. Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. Zhu F; Jin P; Zhu T; Wang W; Ye H; Pan H; Hou L; Li J; Wang X; Wu S; Wang Y; Gou J; Huang H; Wu H; Wang X; Chen W Clin Infect Dis; 2022 Aug; 75(1):e783-e791. PubMed ID: 34551104 [TBL] [Abstract][Full Text] [Related]
13. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672 [TBL] [Abstract][Full Text] [Related]
14. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS; Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. Koblin BA; Casapia M; Morgan C; Qin L; Wang ZM; Defawe OD; Baden L; Goepfert P; Tomaras GD; Montefiori DC; McElrath MJ; Saavedra L; Lau CY; Graham BS; PLoS One; 2011; 6(9):e24517. PubMed ID: 21931737 [TBL] [Abstract][Full Text] [Related]
16. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. Cheng C; Gall JG; Nason M; King CR; Koup RA; Roederer M; McElrath MJ; Morgan CA; Churchyard G; Baden LR; Duerr AC; Keefer MC; Graham BS; Nabel GJ J Virol; 2010 Jan; 84(1):630-8. PubMed ID: 19846512 [TBL] [Abstract][Full Text] [Related]
17. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. Walsh SR; Moodie Z; Fiore-Gartland AJ; Morgan C; Wilck MB; Hammer SM; Buchbinder SP; Kalams SA; Goepfert PA; Mulligan MJ; Keefer MC; Baden LR; Swann EM; Grant S; Ahmed H; Li F; Hertz T; Self SG; Friedrich D; Frahm N; Liao HX; Montefiori DC; Tomaras GD; McElrath MJ; Hural J; Graham BS; Jin X; J Infect Dis; 2016 Feb; 213(4):541-50. PubMed ID: 26475930 [TBL] [Abstract][Full Text] [Related]
18. Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial. Sarwar UN; Novik L; Enama ME; Plummer SA; Koup RA; Nason MC; Bailer RT; McDermott AB; Roederer M; Mascola JR; Ledgerwood JE; Graham BS; PLoS One; 2014; 9(9):e106240. PubMed ID: 25264782 [TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. Sumida SM; Truitt DM; Kishko MG; Arthur JC; Jackson SS; Gorgone DA; Lifton MA; Koudstaal W; Pau MG; Kostense S; Havenga MJ; Goudsmit J; Letvin NL; Barouch DH J Virol; 2004 Mar; 78(6):2666-73. PubMed ID: 14990686 [TBL] [Abstract][Full Text] [Related]